Health Care Buzz Today
Best Buy Leads $5.5M Investment with Valencell. The Series B investment in the mobile health company was joined by TDF and True Ventures. Valencell’s Healthset sensor tracks heart rate, calories burned, steps taken, distance traveled, speed and more through earbuds.
Best Buy Leads $5.5M Investment with Valencell. The Series B investment in the mobile health company was joined by TDF and True Ventures. Valencell’s Healthset sensor tracks heart rate, calories burned, steps taken, distance traveled, speed and more through earbuds.
Once Rare, Infection by Tick Bites Spreads. Babesiosis, a potentially devastating malaria-like infection spread through tick bites, has gained a foothold in the Hudson Valley and the coastal Northeast, researchers have found.
FDA Okays New Abuse-Resistant Opioid. The regulatory agency approved a narcotic painkiller with abuse-deterrent properties, Pfizer has announced. The new drug, Oxecta, uses a “unique composition of commonly used pharmaceutical ingredients” to stop potential abusers from crushing, chewing, snorting, or injecting the opioid.
FDA Issues Draft Guidance for Artificial Pancreas. Addressed in the FDA’s document is a Low Glucose Suspend System, which can reduce the severity of hypoglycemic episodes by temporarily reducing insulin delivery. The early-stage system requires patients to manage glucose levels with a meter and give themselves insulin as needed.
Crow’s Feet Faceoff Yields Clear Winner. Crow’s feet responded significantly better to treatment with abobotulinumtoxinA (Dysport) than with onabotulinumtoxinA (Botox), according to results of the first-ever randomized comparison of the two botulinum toxin compounds.
